drugset / Trial / NCT05847764
Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Disitamab Vedotin combined therapy locally advanced or metastatic NSCLC Patients with HER2 Alterations.
Timeline
- Start
- 2023-05
- Primary completion
- 2024-10
- Completion
- 2025-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | — | — |
| Subject | Firmonertinib | Small molecule | — | — |
| Subject | Tislelizumab | Monoclonal antibody | — | — |